Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04806503 · ClinicalTrials.gov registry record · Phase 2
A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 234
- Enrollment target
NCT04806503 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 234 participants.
The verdict
NCT04806503, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 234 participants
- Enrollment target
Study Summary
Study of safety and efficacy of UNR844 in subjects with presbyopia.
Interventions
- DRUG Placebo
- DRUG UNR844
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2022-10-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04806503
The ClinicalTrials.gov registry entry for NCT04806503 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04806503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04806503 about?
NCT04806503 is a clinical study titled "A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.". Study of safety and efficacy of UNR844 in subjects with presbyopia.
What is the current status of trial NCT04806503?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 234 participants. The study started on 2021-06-30. Estimated completion is 2022-10-14.
What interventions are being tested in trial NCT04806503?
The interventions under investigation include: Placebo (DRUG), UNR844 (DRUG).
Who is sponsoring clinical trial NCT04806503?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.